Mortality from stroke has been declining in New Zealand since 1950 and at an accelerating rate since the early 1970s. Hypertension is the single most important risk factor for stroke. The temporal association between the recent decline in mortality and an increase in the proportion of patients with hypertension detected and treated led to the assumption of a cause and effect relation.
Introduction
Mortality from stroke has been declining steadily in New Zealand and elsewhere for several decades," and the decline accelerated in the early 1970s, particularly among women." I This decline could have been caused by a decrease in the incidence of stroke or improved rates of survival, or both. The most plausible explanation is that the incidence has fallen, although the evidence is as yet incomplete.6 Hypertension is the most important risk factor for stroke.7 Improved management of hypertension has been proposed as the main reason for the recent decline in mortality from stroke. 48 Antihypertensive drugs have been available since the early 1950s, although the range of agents and their acceptability have increased considerably over the past 15 years. In several countries, including New Zealand, the detection, treatment, and control of hypertension have improved considerably over the past two decades.8'
The greater decrease in mortality recently observed in women is consistent with the fact that more women than men are currently receiving (and using) antihypertensive treatment. 4 This relation has not, however, been quantitatively assessed. This paper estimates the contribution of improved treatment of hypertension to the decline in mortality from stroke in New Zealand. When the analysis was adjusted to take into consideration the 18% of patients in this age range who had had recurrent strokes the number of deaths to be explained was reduced to 334.12 This increased the contribution of control of hypertension to the decline in mortality from stroke to 90/o, which perhaps provides a fairer comparison with figures for subjects in the Australian trial, none of whom had a history of stroke before entry.
The Hypertension Detection and Follow up Program compared patients with hypertension (diastolic blood pressure s90 mm Hg, including those already receiving treatment for hypertension) receiving stepped care with those treated in the community. Amopg white participants a reduction in deaths from strke occurred only in-the patients aged,60-69, being 0-89 and 1P61/1000 for men and women, respectively. Thus treatment of 14 180 extra people aged 60-69 in 1982 compared with 1973 would be expected to have reduced the number ofdeaths from stroke by 23. This represents 9 5% ofthe observed decline in those aged 60-69 (or 5-7% ofthe total observed decline in those aged 30-69).
Discussion
The temporal association between-the recent decline in mortality from stroke in New Zealand and the improvement in the detection and treatment of hypertension has been striking in New Zealand and many other countries." 5 This study suggests that less than 10% of the observed decline in mortality from stroke between 1973 and 1982 in New Zealanders aged 30-69 resulted from an increase in the proportion of people' receiving pharmacological treatment for hypertension, as judged from randomised controlled trials conducted overseas.
Several assumptions were made in reaching these conclusions. Firstly, we applied the results,from trials of the treatment of mild hypertension. Treatment of hypertension may be more effective in those with more severe disease, though only 12% ofall patients with hypertension aged 35-64,in Auckland had a diastolic blood pressure ¢ 105 mm Hg.9 It was reassuring that both trials produced-similar estimates of the contribution of changes in the proportion of people receiving pharmacological treatment for hypertension. If anything, it could be argued that these estimates were generous as the level of control achieved in clinical trials is unlikely to occur in the general population.
It was also necessary to extrapolate from studies in Napier and Auckland to the total population ofNew Zealand because ofthe lack of comparable national studies. The prevalence of hypertension in the city of Napier, however, was similar to that observed in a rural community in New Zealand in 1975, supporting our assumption.'6 Furthermore, the sampling frame in the 1982 Auckland study included almost one quarter ofthe total population ofNew Zealand.
The present assessment of the impact of treatment was based on mortality data for two separate years, 1973 and 1982. Mortality in the decade before 1973 was, however, relatively stable, and the decline after 1973 was consistent for all age groups and both sexes. Although we concentrated on the decline in the past decade, mortality from stroke in New Zealand has been declining at least since the 1950s; the overall decline thus began before effective antihypertensive treatment was available.' Furthermore, as the table indicates, three quarters of the reduction in mortality occurred in peolile-aged over 70, yet the medical profession was more cautious in treating elderly patients with hypertension during this period.
The influence of secular trends on other risk factors for stroke such as serum lipid concentrations, blood glucose concentrations, oral contraceptives, diet, and cigarette smoking has not been investigated systematically. As these risk factors do not have consistently strong associations with stroke,'7 however, it is unlikely that changes in the extent to which the population has been affected by these factors would explain much of the decline-for example, it has been shown that serum lipid concentrations have no consistent association with stroke. '7 It is thus doubtful that the apparent recent decline in cholesterol concentrations in New Zealand'8 would have had a substantial effect on the incidence of stroke or mortality, particularly as the decline in cholesterol concentrations apparently began much lgiter than the fall in mortality from stroke. Diabetes accelerates the atherosclerotic process, but there is a low relative risk of stroke in non-hypertensive diabetics."9 Furthermore, it is unlikely that there has been a decline in the prevalence ofdiabetes or any major improvement in its management.
Cigarette smoking, on the other hand, has been shown to be an important risk factor for stroke in the population of Auckland; a synergistic effect between smoking and the treatment of hypertension has also been observed (Bonita R, et al; unpublished results). There has been-an acceleration in the decline of tobacco consumption since the mid 1970s,20 and trends in cigarette smoking may have contributed more to the decline in mortality from stroke than has previously been recognised.;
Although the risk of stroke in patients with transient ischaemic attack is high, the occurrence of transient -ischaemic attack in the population is low. Surgical procedures such as carotid endarterectomy have yet to be proved to be effective,21 and only a few such operations are performed in New Zealand.
Other risk factors (not defined here) may have contributed to the decline.22 Presumably those factors responsible for the decline in mortality that occurred before the widespread use of antihypertensive drugs are still important. It is also possible that small changes in the mean blood pressure of the population may have had a more pronounced effect on mortality from stroke than the treatment of hypertension. Unfortunately, there has been no adequate assessment of trends, in mean blood pressure in the population of New Zealaud.
Trends in cardiovascular disease are often cited to justify public health priorities and medical practice.23 Factors other than antihypertensive treatment appear to have contributed most to the decline in mortality from stroke. Information on long term trends in the incidence of stroke and survival is required. Before more xesources are directed towards promoting pharmacological treatment of hypertension greater effort should perhaps be made to increase understanding of the reasons for the decline in the mortality from stroke.
